+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Retinal Disease Therapy Options Market by Indication, Therapy Type, Route Of Administration, End User, Distribution Channel - Global Forecast to 2030- Product Image
Retinal Disease Therapy Options Market by Indication, Therapy Type, Route Of Administration, End User, Distribution Channel - Global Forecast to 2030- Product Image
Sale

Retinal Disease Therapy Options Market by Indication, Therapy Type, Route Of Administration, End User, Distribution Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 194 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6085119
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The retinal disease therapy market is experiencing significant transformation as advanced technologies, evolving regulation, and increasing patient demand reshape treatment standards. As healthcare systems respond to rising disease prevalence, a clear understanding of current trends and challenges is essential for effective decision-making.

Market Snapshot: Retinal Disease Therapy Market Outlook

The global retinal disease therapy market is witnessing robust growth, fueled by demographic shifts, lifestyle factors, and widespread adoption of innovative biologic treatments. Market size and CAGR projections reflect the expanding role of advanced therapies across a broadening patient base. Strengthened by developments in diagnostic imaging and digital health, the sector is characterized by an accelerated pace of product launches and strategic partnerships among major manufacturers, regional distributors, and healthcare networks. Changing reimbursement frameworks and technological breakthroughs continue to drive competitive evolution in this dynamic environment.

Scope & Segmentation

This report provides comprehensive analysis across all key aspects of the retinal disease therapy market, enabling targeted strategy development and resource allocation.

  • Indications: Diabetic retinopathy, retinal vein occlusion, and wet age-related macular degeneration, with deep dives into nonproliferative and proliferative presentations, classic and occult lesion distinctions, and management of branch versus central vein occlusions.
  • Therapy Types: Laser photocoagulation (focal grid and panretinal), photodynamic therapy, pharmacologic regimens including anti-VEGF agents (aflibercept, bevacizumab, ranibizumab), corticosteroid implants (dexamethasone, fluocinolone), and surgical interventions tailored for complex retinal complications.
  • Routes of Administration: Intravitreal injection, systemic (intravenous and oral), and topical delivery approaches, each supporting different aspects of patient management and therapy choice.
  • End Users: Ambulatory surgical centers, hospitals, specialty clinics, and home care models, reflecting a shift toward decentralized management and patient-centric care pathways.
  • Distribution Channels: Hospital pharmacies, retail pharmacies, and online outlets ensure access across care settings, responding to demand for both convenience and regulatory assurance.
  • Regional Coverage: Market insights span Americas (including United States, Brazil, Argentina, Canada, and Mexico), Europe, Middle East, and Africa (across 20+ territories), and Asia-Pacific (including China, India, Japan, South Korea, Australia, and key Southeast Asian markets).
  • Leading Companies: Analysis profiles Regeneron Pharmaceuticals, F. Hoffmann-La Roche, Novartis, Bayer, AbbVie, Bausch Health Companies, Apellis Pharmaceuticals, Spark Therapeutics, Iveric Bio, and Alimera Sciences, together shaping global competitive strategy.
[ImageId=GUID]

Key Takeaways

  • Growing disease complexity and earlier patient identification require integration of advanced diagnostics, molecular profiling, and data-driven management tools into standard of care protocols.
  • Therapy innovation—spanning anti-VEGF biologics, gene therapy, and cell-based treatments—is extending treatment durability, customizing approaches to individual risk, and challenging reliance on single-modality regimens.
  • Regional variation in regulatory pathways, reimbursement policies, and care infrastructure shapes access to novel therapies, necessitating tailored market entry and partnership strategies by manufacturers.
  • Intravitreal injection remains the foundation of drug delivery, but sustained-delivery implants and digital monitoring platforms are broadening options for both clinicians and patients.
  • Mergers, acquisitions, and cross-industry alliances are driving rapid expansion into emerging technology domains—including diagnostic imaging, artificial intelligence, and miniaturized devices—and enabling life cycle management for established products.

Tariff Impact: Adjusting to the 2025 US Pharmaceutical Tariffs

Revised US tariff policies in 2025 have altered cost structures for imported pharmaceuticals and medical devices essential to retinal care. Manufacturers are refining sourcing models and inventory strategies, including regional diversification and local assembly, to offset increased duties. Clinics and networks are leveraging purchase consortia and exploring preferential trade agreements to optimize acquisition costs and safeguard access. These adjustments foster supply chain resilience and promote continued investment in innovative therapies despite near-term economic pressures.

Methodology & Data Sources

This report utilizes a robust combination of primary and secondary research. Experts in ophthalmology, supply chain management, and market access provided firsthand insights via interviews. An in-depth review of academic literature, regulatory filings, and proprietary databases ensured comprehensive market intelligence. Data triangulation and validation processes underpin the accuracy and reliability of the analysis presented.

Why This Report Matters

  • Equips senior executives and strategic planners with actionable intelligence on evolving market trends, enabling informed investment, pipeline, and commercialization decisions.
  • Supports identification of partnership, distribution, and innovation opportunities within the changing regulatory and reimbursement environment.

Conclusion

The retinal disease therapy market is entering a phase defined by rapid technological progress, greater segmentation, and heightened strategy complexity. Stakeholders who monitor these dynamics closely are positioned to enhance patient outcomes while optimizing business growth.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Retinal Disease Therapy Options Market, by Indication
8.1. Introduction
8.2. Diabetic Retinopathy
8.2.1. Nonproliferative Diabetic Retinopathy
8.2.2. Proliferative Diabetic Retinopathy
8.3. Retinal Vein Occlusion
8.3.1. Branch Retinal Vein Occlusion
8.3.2. Central Retinal Vein Occlusion
8.4. Wet Age-Related Macular Degeneration
8.4.1. Classic
8.4.2. Occult
9. Retinal Disease Therapy Options Market, by Therapy Type
9.1. Introduction
9.2. Laser Therapy
9.2.1. Photocoagulation
9.2.1.1. Focal Grid Photocoagulation
9.2.1.2. Panretinal Photocoagulation
9.2.2. Photodynamic Therapy
9.3. Pharmacologic Therapy
9.3.1. Anti-Vegf Agents
9.3.1.1. Aflibercept
9.3.1.2. Bevacizumab
9.3.1.3. Ranibizumab
9.3.2. Corticosteroids
9.3.2.1. Dexamethasone Implant
9.3.2.2. Fluocinolone Implant
9.4. Surgical Intervention
10. Retinal Disease Therapy Options Market, by Route Of Administration
10.1. Introduction
10.2. Intravitreal Injection
10.3. Systemic Administration
10.3.1. Intravenous Administration
10.3.2. Oral Administration
10.4. Topical Administration
11. Retinal Disease Therapy Options Market, by End User
11.1. Introduction
11.2. Ambulatory Surgical Centers
11.3. Home Care Settings
11.4. Hospitals
11.5. Specialty Clinics
12. Retinal Disease Therapy Options Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacies
12.3. Online Pharmacies
12.4. Retail Pharmacies
13. Americas Retinal Disease Therapy Options Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Retinal Disease Therapy Options Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Retinal Disease Therapy Options Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Regeneron Pharmaceuticals, Inc.
16.3.2. F. Hoffmann-La Roche AG
16.3.3. Novartis AG
16.3.4. Bayer AG
16.3.5. AbbVie Inc.
16.3.6. Bausch Health Companies Inc.
16.3.7. Apellis Pharmaceuticals, Inc.
16.3.8. Spark Therapeutics, Inc.
16.3.9. Iveric Bio, Inc.
16.3.10. Alimera Sciences, Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. RETINAL DISEASE THERAPY OPTIONS MARKET MULTI-CURRENCY
FIGURE 2. RETINAL DISEASE THERAPY OPTIONS MARKET MULTI-LANGUAGE
FIGURE 3. RETINAL DISEASE THERAPY OPTIONS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. RETINAL DISEASE THERAPY OPTIONS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. RETINAL DISEASE THERAPY OPTIONS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. RETINAL DISEASE THERAPY OPTIONS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DIABETIC RETINOPATHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY NONPROLIFERATIVE DIABETIC RETINOPATHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PROLIFERATIVE DIABETIC RETINOPATHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY RETINAL VEIN OCCLUSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY BRANCH RETINAL VEIN OCCLUSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY CENTRAL RETINAL VEIN OCCLUSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY WET AGE-RELATED MACULAR DEGENERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY CLASSIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY OCCULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY WET AGE-RELATED MACULAR DEGENERATION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY LASER THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PHOTOCOAGULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY FOCAL GRID PHOTOCOAGULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PANRETINAL PHOTOCOAGULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PHOTOCOAGULATION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PHARMACOLOGIC THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY ANTI-VEGF AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY AFLIBERCEPT, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY RANIBIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DEXAMETHASONE IMPLANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY FLUOCINOLONE IMPLANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY SURGICAL INTERVENTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY INTRAVITREAL INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY SYSTEMIC ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY SYSTEMIC ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY TOPICAL ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY WET AGE-RELATED MACULAR DEGENERATION, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PHOTOCOAGULATION, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY SYSTEMIC ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY WET AGE-RELATED MACULAR DEGENERATION, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PHOTOCOAGULATION, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY SYSTEMIC ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 85. CANADA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 86. CANADA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2030 (USD MILLION)
TABLE 87. CANADA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2030 (USD MILLION)
TABLE 88. CANADA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY WET AGE-RELATED MACULAR DEGENERATION, 2018-2030 (USD MILLION)
TABLE 89. CANADA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 90. CANADA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 91. CANADA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PHOTOCOAGULATION, 2018-2030 (USD MILLION)
TABLE 92. CANADA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2030 (USD MILLION)
TABLE 93. CANADA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 94. CANADA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 95. CANADA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 96. CANADA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY SYSTEMIC ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 97. CANADA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 98. CANADA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 99. MEXICO RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 100. MEXICO RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2030 (USD MILLION)
TABLE 101. MEXICO RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2030 (USD MILLION)
TABLE 102. MEXICO RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY WET AGE-RELATED MACULAR DEGENERATION, 2018-2030 (USD MILLION)
TABLE 103. MEXICO RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 104. MEXICO RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 105. MEXICO RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PHOTOCOAGULATION, 2018-2030 (USD MILLION)
TABLE 106. MEXICO RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2030 (USD MILLION)
TABLE 107. MEXICO RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 108. MEXICO RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 109. MEXICO RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 110. MEXICO RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY SYSTEMIC ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 111. MEXICO RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 112. MEXICO RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY WET AGE-RELATED MACULAR DEGENERATION, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PHOTOCOAGULATION, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY SYSTEMIC ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 126. BRAZIL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 127. ARGENTINA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 128. ARGENTINA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2030 (USD MILLION)
TABLE 129. ARGENTINA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2030 (USD MILLION)
TABLE 130. ARGENTINA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY WET AGE-RELATED MACULAR DEGENERATION, 2018-2030 (USD MILLION)
TABLE 131. ARGENTINA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 132. ARGENTINA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 133. ARGENTINA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PHOTOCOAGULATION, 2018-2030 (USD MILLION)
TABLE 134. ARGENTINA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2030 (USD MILLION)
TABLE 135. ARGENTINA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 136. ARGENTINA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 137. ARGENTINA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 138. ARGENTINA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY SYSTEMIC ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 139. ARGENTINA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 140. ARGENTINA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2030 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY WET AGE-RELATED MACULAR DEGENERATION, 2018-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PHOTOCOAGULATION, 2018-2030 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY SYSTEMIC ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 156. UNITED KINGDOM RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 157. UNITED KINGDOM RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2030 (USD MILLION)
TABLE 158. UNITED KINGDOM RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2030 (USD MILLION)
TABLE 159. UNITED KINGDOM RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY WET AGE-RELATED MACULAR DEGENERATION, 2018-2030 (USD MILLION)
TABLE 160. UNITED KINGDOM RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 161. UNITED KINGDOM RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 162. UNITED KINGDOM RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PHOTOCOAGULATION, 2018-2030 (USD MILLION)
TABLE 163. UNITED KINGDOM RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2030 (USD MILLION)
TABLE 164. UNITED KINGDOM RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 165. UNITED KINGDOM RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 166. UNITED KINGDOM RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 167. UNITED KINGDOM RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY SYSTEMIC ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 168. UNITED KINGDOM RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 169. UNITED KINGDOM RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 170. GERMANY RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 171. GERMANY RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2030 (USD MILLION)
TABLE 172. GERMANY RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2030 (USD MILLION)
TABLE 173. GERMANY RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY WET AGE-RELATED MACULAR DEGENERATION, 2018-2030 (USD MILLION)
TABLE 174. GERMANY RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 175. GERMANY RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 176. GERMANY RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PHOTOCOAGULATION, 2018-2030 (USD MILLION)
TABLE 177. GERMANY RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2030 (USD MILLION)
TABLE 178. GERMANY RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 179. GERMANY RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 180. GERMANY RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 181. GERMANY RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY SYSTEMIC ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 182. GERMANY RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 183. GERMANY RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 184. FRANCE RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 185. FRANCE RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2030 (USD MILLION)
TABLE 186. FRANCE RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2030 (USD MILLION)
TABLE 187. FRANCE RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY WET AGE-RELATED MACULAR DEGENERATION, 2018-2030 (USD MILLION)
TABLE 188. FRANCE RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 189. FRANCE RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 190. FRANCE RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PHOTOCOAGULATION, 2018-2030 (USD MILLION)
TABLE 191. FRANCE RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2030 (USD MILLION)
TABLE 192. FRANCE RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 193. FRANCE RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 194. FRANCE RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 195. FRANCE RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY SYSTEMIC ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 196. FRANCE RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 197. FRANCE RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 198. RUSSIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 199. RUSSIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2030 (USD MILLION)
TABLE 200. RUSSIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2030 (USD MILLION)
TABLE 201. RUSSIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY WET AGE-RELATED MACULAR DEGENERATION, 2018-2030 (USD MILLION)
TABLE 202. RUSSIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 203. RUSSIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 204. RUSSIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PHOTOCOAGULATION, 2018-2030 (USD MILLION)
TABLE 205. RUSSIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2030 (USD MILLION)
TABLE 206. RUSSIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 207. RUSSIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 208. RUSSIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 209. RUSSIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY SYSTEMIC ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 210. RUSSIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 211. RUSSIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 212. ITALY RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 213. ITALY RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2030 (USD MILLION)
TABLE 214. ITALY RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2030 (USD MILLION)
TABLE 215. ITALY RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY WET AGE-RELATED MACULAR DEGENERATION, 2018-2030 (USD MILLION)
TABLE 216. ITALY RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 217. ITALY RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 218. ITALY RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PHOTOCOAGULATION, 2018-2030 (USD MILLION)
TABLE 219. ITALY RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2030 (USD MILLION)
TABLE 220. ITALY RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 221. ITALY RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 222. ITALY RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 223. ITALY RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY SYSTEMIC ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 224. ITALY RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 225. ITALY RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 226. SPAIN RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 227. SPAIN RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2030 (USD MILLION)
TABLE 228. SPAIN RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2030 (USD MILLION)
TABLE 229. SPAIN RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY WET AGE-RELATED MACULAR DEGENERATION, 2018-2030 (USD MILLION)
TABLE 230. SPAIN RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 231. SPAIN RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 232. SPAIN RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PHOTOCOAGULATION, 2018-2030 (USD MILLION)
TABLE 233. SPAIN RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2030 (USD MILLION)
TABLE 234. SPAIN RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 235. SPAIN RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 236. SPAIN RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 237. SPAIN RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY SYSTEMIC ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 238. SPAIN RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 239. SPAIN RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 240. UNITED ARAB EMIRATES RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 241. UNITED ARAB EMIRATES RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2030 (USD MILLION)
TABLE 242. UNITED ARAB EMIRATES RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2030 (USD MILLION)
TABLE 243. UNITED ARAB EMIRATES RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY WET AGE-RELATED MACULAR DEGENERATION, 2018-2030 (USD MILLION)
TABLE 244. UNITED ARAB EMIRATES RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 245. UNITED ARAB EMIRATES RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 246. UNITED ARAB EMIRATES RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PHOTOCOAGULATION, 2018-2030 (USD MILLION)
TABLE 247. UNITED ARAB EMIRATES RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2030 (USD MILLION)
TABLE 248. UNITED ARAB EMIRATES RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 249. UNITED ARAB EMIRATES RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 250. UNITED ARAB EMIRATES RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 251. UNITED ARAB EMIRATES RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY SYSTEMIC ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 252. UNITED ARAB EMIRATES RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 253. UNITED ARAB EMIRATES RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 254. SAUDI ARABIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 255. SAUDI ARABIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2030 (USD MILLION)
TABLE 256. SAUDI ARABIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2030 (USD MILLION)
TABLE 257. SAUDI ARABIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY WET AGE-RELATED MACULAR DEGENERATION, 2018-2030 (USD MILLION)
TABLE 258. SAUDI ARABIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 259. SAUDI ARABIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 260. SAUDI ARABIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PHOTOCOAGULATION, 2018-2030 (USD MILLION)
TABLE 261. SAUDI ARABIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2030 (USD MILLION)
TABLE 262. SAUDI ARABIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 263. SAUDI ARABIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 264. SAUDI ARABIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 265. SAUDI ARABIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY SYSTEMIC ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 266. SAUDI ARABIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 267. SAUDI ARABIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 268. SOUTH AFRICA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 269. SOUTH AFRICA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2030 (USD MILLION)
TABLE 270. SOUTH AFRICA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2030 (USD MILLION)
TABLE 271. SOUTH AFRICA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY WET AGE-RELATED MACULAR DEGENERATION, 2018-2030 (USD MILLION)
TABLE 272. SOUTH AFRICA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 273. SOUTH AFRICA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 274. SOUTH AFRICA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PHOTOCOAGULATION, 2018-2030 (USD MILLION)
TABLE 275. SOUTH AFRICA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PHARMACOLOGIC THERAPY, 2018-2030 (USD MILLION)
TABLE 276. SOUTH AFRICA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 277. SOUTH AFRICA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 278. SOUTH AFRICA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 279. SOUTH AFRICA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY SYSTEMIC ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 280. SOUTH AFRICA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 281. SOUTH AFRICA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 282. DENMARK RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 283. DENMARK RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2030 (USD MILLION)
TABLE 284. DENMARK RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2030 (USD MILLION)
TABLE 285. DENMARK RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY WET AGE-RELATED MACULAR DEGENERATION, 2018-2030 (USD MILLION)
TABLE 286. DENMARK RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 287. DENMARK RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY LASER THERAPY, 2018

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Retinal Disease Therapy Options market report include:
  • Regeneron Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche AG
  • Novartis AG
  • Bayer AG
  • AbbVie Inc.
  • Bausch Health Companies Inc.
  • Apellis Pharmaceuticals, Inc.
  • Spark Therapeutics, Inc.
  • Iveric Bio, Inc.
  • Alimera Sciences, Inc.

Related Topics

Related Reports

Inherited Retinal Disease Market Report 2025 - Product Image

Inherited Retinal Disease Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Retinal Disorder Treatment Market by Disease, Drug Class, Route Of Administration, End User, Distribution Channel - Global Forecast to 2030 - Product Image

Retinal Disorder Treatment Market by Disease, Drug Class, Route Of Administration, End User, Distribution Channel - Global Forecast to 2030

  • Report
  • 180 Pages
  • Global
From
Retinal Laser Photocoagulation - Global Strategic Business Report - Product Image

Retinal Laser Photocoagulation - Global Strategic Business Report

  • Report
  • 66 Pages
  • Global
From
Retinal Vein Occlusion Treatment Market by Treatment Type, Age Group, Condition Type, End User - Global Forecast to 2030 - Product Image

Retinal Vein Occlusion Treatment Market by Treatment Type, Age Group, Condition Type, End User - Global Forecast to 2030

  • Report
  • 192 Pages
  • Global
From
Retinal Vein Occlusion Treatment - Global Strategic Business Report - Product Image

Retinal Vein Occlusion Treatment - Global Strategic Business Report

  • Report
  • 73 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.